JENKINS v. BP EXPLORATION & PRODUCTION INC

CourtDistrict Court, N.D. Florida
DecidedMarch 30, 2023
Docket5:19-cv-00260
StatusUnknown

This text of JENKINS v. BP EXPLORATION & PRODUCTION INC (JENKINS v. BP EXPLORATION & PRODUCTION INC) is published on Counsel Stack Legal Research, covering District Court, N.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
JENKINS v. BP EXPLORATION & PRODUCTION INC, (N.D. Fla. 2023).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF FLORIDA PENSACOLA DIVISION

IN RE: DEEPWATER HORIZON Case No. 3:19cv963 BELO CASES This Document Relates to: Judge M. Casey Rodgers Magistrate Judge Hope T. Cannon Lester Jenkins, 5:19cv260 Dwight Siples, 5:19cv310 Kenneth Davenport, 5:18cv245 Michael Moulder, 5:19cv12

ORDER Before the Court is the Order and Report and Recommendation of the Magistrate Judge dated December 15, 2022, ECF No. 570 (Master Docket), in the above-named Back-End Litigation Option (“BELO”) cases, recommending the exclusion of Plaintiffs’ general causation experts under Federal Rule of Evidence 702 and Daubert;1 striking a supplemental report; and recommending the grant of summary judgment in favor of Defendants BP Exploration & Production, Inc. and BP America Production Company (collectively “BP” or the “BP Defendants”).2 The

1 Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579 (1993). 2 The Court assumes the parties’ familiarity with the BELO context and basic facts of the Deepwater Horizon oil spill and resulting multidistrict litigation, which resolved in part through a Medical Benefits Class Action Settlement Agreement (“Settlement”). The Settlement provided a claim payment scheme for all class members who suffered an illness that was diagnosed by the Settlement cutoff date of April 16, 2012. The Settlement also established a procedure to allow certain medical benefits class members to bring a back-end lawsuit (a BELO suit) to recover for later-manifested physical conditions (“LMPCs”) first diagnosed after the settlement date of April 16, 2012, and which are claimed to have been caused by exposure to chemicals originating from the spill and/or cleanup response activities. The multidistrict litigation background and the context Page 2 of 13

Plaintiffs have filed timely objections pursuant to Title 28, United States Code, Section 636(b)(1), see ECF Nos. 577 & 578, which are ripe for consideration. 1. Briefly summarized, the operative facts reflect that the above-named Plaintiffs suffer from chronic ocular and sinus diseases, which they contend were caused by

exposure to toxic oil-based chemicals when they engaged in cleanup work along the Gulf Coast of Florida after the Deepwater Horizon oil spill.3 Because these conditions were diagnosed after the cutoff date for claims eligible for a settlement

payment under the Deepwater Horizon Medical Benefits Class Action Settlement Agreement, they are deemed “later-manifested physical conditions” (“LMPCs”) under the terms of the settlement, which means Plaintiffs had to bring the instant BELO suits to recover compensation for their injuries, see supra Note 2.

To succeed in this toxic tort context, Plaintiffs must show through expert testimony that a chemical or mixture of chemicals from the oil spill caused their LMPCs. See In re Deepwater Horizon BELO Cases, No. 3:19-963, 2020 WL

and facts of the cases at issue are adequately laid out within the Report and Recommendation, which is adopted herein by reference, and thus need not be stated in full in this Order. 3 Plaintiffs Kenneth Davenport and Michael Moulder complain of ocular conditions (Keratoconjunctivitis Sicca and chronic eye irritation/chronic conjunctivitis), and Plaintiffs Lester Jenkins and Dwight Siples complain of a sinus condition (chronic sinusitis). Case No. 3:19cv963-MCR-HTC Page 3 of 13

6689212 (N.D. Fla. Nov. 4, 2020), aff’d sub nom., Griffin v. BP Expl. & Prod., 2022 WL 104243 (11th Cir. Jan. 11, 2022). This causation inquiry requires a showing of both general causation and specific causation. See McClain v. Metabolife Int’l, Inc., 401 F.3d 1233, 1239 (11th Cir. 2005). In an effort to structure the expert work in a way that would present the causation issues efficiently and cost-effectively, the

Court selected eight test cases and established a bifurcated procedure by which the general causation issue would be resolved first.4 Plaintiffs designated experts on the issue of general causation—Dr. Gina Solomon, Dr. David Carpenter, Dr. Michael

Freeman, and Dr. Ranajit Sahu, and BP has challenged their reliability and helpfulness under Rule 702 and Daubert and moved for summary judgment.5 Plaintiffs responded with expert supplemental declarations, including a supplemental report by Dr. Freeman, and requested an evidentiary hearing. The

4 Of the eight test cases selected, the above-named cases remain and are represented by the Downs Law Group. All other BELO cases represented by the Downs Law Group that involve the same categories of alleged injuries (ocular and sinus) were stayed by consent of the parties pending resolution of the general causation issue. Those plaintiffs also agree to be bound by the Court’s ruling in the test cases, after appeal if any, and they agree that their cases should be dismissed with prejudice and without further litigation if the general causation issue is resolved against them. See ECF Nos. 342, 348 (Master Docket). 5 Plaintiffs also designated Dr. James J.J. Clark, whom they withdrew for purposes of general causation at the oral argument, and Dr. Robert Cykiert and Dr. David Greene, who offered an expert opinion on diagnosis. The Magistrate Judge found BP’s motions to exclude these witnesses moot in light of the ultimate decision that summary judgment should be granted in favor of BP for the lack of proof on general causation. Case No. 3:19cv963-MCR-HTC Page 4 of 13

undersigned referred the Daubert and summary judgment motions to the Magistrate Judge for a report and recommendation. The Magistrate Judge denied the request for a hearing but allowed extensive oral argument, following which she entered a detailed and lengthy Report and Recommendation (“R&R). The R&R reflects a thorough gatekeeping analysis under

Rule 702 and Daubert. In the R&R, the Magistrate Judge concluded that the Plaintiffs failed to support their general causation contention with a scientifically reliable expert opinion. The Magistrate Judge rejected Plaintiffs’ overarching

contention that their experts should not be required to identify a harmful level or dose of exposure at which any particular chemical within the oil is capable of causing the LMPCs at issue, finding the argument misplaced and unsupported by law. Ultimately, after considering each expert’s opinion in turn, the Magistrate Judge

recommended granting the Daubert motions and excluding each expert’s opinion as unreliable and/or unhelpful. Among the deficiencies noted were the failure to identify a reliable statistically significant association in the literature for the chronic

LMPCs claimed, as opposed to identifying only self-reported symptoms or acute conditions; the failure to fully evaluate or explain the study limitations or to explain how the expert’s application of the Bradford Hill criteria supported a causal inference for the LMPC’s claimed in light of, or despite, the study limitations; the Case No. 3:19cv963-MCR-HTC Page 5 of 13

failure to identify or discuss a harmful threshold level of exposure or dose capable of causing the LMPCs at issue; and the failure to consider the background risk of disease. The Magistrate Judge also granted the motion to strike Dr. Freeman’s supplemental report, and portions of his supplemental declaration referring to it, as untimely disclosed opinions. Plaintiffs object, and BP has responded.

2. When reviewing a report and recommendation, the Court must “make a de novo determination of those portions of the report or specified proposed findings or

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Colleen Macort v. Prem, Inc.
208 F. App'x 781 (Eleventh Circuit, 2006)
Bonnie Joyce Rider v. Sandoz Pharmaceuticals
295 F.3d 1194 (Eleventh Circuit, 2002)
Johnny C. McClain v. Metabolife International, Inc
401 F.3d 1233 (Eleventh Circuit, 2005)
Shernika Holton v. City of Thomasville School
425 F.3d 1325 (Eleventh Circuit, 2005)
United States v. United States Gypsum Co.
333 U.S. 364 (Supreme Court, 1948)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Hendrix Ex Rel. Gp v. Evenflo Co., Inc.
609 F.3d 1183 (Eleventh Circuit, 2010)
Douglas C. Kilpatrick v. Breg, Inc.
613 F.3d 1329 (Eleventh Circuit, 2010)
TFWS, Inc. v. Franchot
572 F.3d 186 (Fourth Circuit, 2009)
Botta v. Barnhart
475 F. Supp. 2d 174 (E.D. New York, 2007)
Cox Enterprises, Inc. v. News-Journal Corporation
794 F.3d 1259 (Eleventh Circuit, 2015)
In re Abilify (Aripiprazole) Prods. Liab. Litig.
299 F. Supp. 3d 1291 (N.D. Florida, 2018)
Malibu Media, LLC v. John Does 1, 2, 4-7, 11, 16, 17, & 21
923 F. Supp. 2d 1339 (M.D. Florida, 2013)
Edgewater Hospital, Inc. v. Bowen
866 F.2d 228 (Seventh Circuit, 1988)
United States v. Philip Esformes
60 F.4th 621 (Eleventh Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
JENKINS v. BP EXPLORATION & PRODUCTION INC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jenkins-v-bp-exploration-production-inc-flnd-2023.